Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design

Pren Naidoo, Rory Dunbar, Carl Lombard, Elizabeth du Toit, Judy Caldwell, Anne Detjen, S Bertel Squire, Donald A Enarson, Nulda Beyers, Pren Naidoo, Rory Dunbar, Carl Lombard, Elizabeth du Toit, Judy Caldwell, Anne Detjen, S Bertel Squire, Donald A Enarson, Nulda Beyers

Abstract

Setting: Primary health services in Cape Town, South Africa.

Study aim: To compare tuberculosis (TB) diagnostic yield in an existing smear/culture-based and a newly introduced Xpert® MTB/RIF-based algorithm.

Methods: TB diagnostic yield (the proportion of presumptive TB cases with a laboratory diagnosis of TB) was assessed using a non-randomised stepped-wedge design as sites transitioned to the Xpert® based algorithm. We identified the full sequence of sputum tests recorded in the electronic laboratory database for presumptive TB cases from 60 primary health sites during seven one-month time-points, six months apart. Differences in TB yield and temporal trends were estimated using a binomial regression model.

Results: TB yield was 20.9% (95% CI 19.9% to 22.0%) in the smear/culture-based algorithm compared to 17.9% (95%CI 16.4% to 19.5%) in the Xpert® based algorithm. There was a decline in TB yield over time with a mean risk difference of -0.9% (95% CI -1.2% to -0.6%) (p<0.001) per time-point. When estimates were adjusted for the temporal trend, TB yield was 19.1% (95% CI 17.6% to 20.5%) in the smear/culture-based algorithm compared to 19.3% (95% CI 17.7% to 20.9%) in the Xpert® based algorithm with a risk difference of 0.3% (95% CI -1.8% to 2.3%) (p = 0.796). Culture tests were undertaken for 35.5% of smear-negative compared to 17.9% of Xpert® negative low MDR-TB risk cases and for 82.6% of smear-negative compared to 40.5% of Xpert® negative high MDR-TB risk cases in respective algorithms.

Conclusion: Introduction of an Xpert® based algorithm did not produce the expected increase in TB diagnostic yield. Studies are required to assess whether improving adherence to the Xpert® negative algorithm for HIV-infected individuals will increase yield. In light of the high cost of Xpert®, a review of its role as a screening test for all presumptive TB cases may be warranted.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Testing protocols in the smear/culture…
Fig 1. Testing protocols in the smear/culture and Xpert® based TB diagnostic algorithms in PHC facilities in Cape Town.
The diagram shows the simplified sequence of TB diagnostic tests recommended in each algorithm and the action taken based on test results. Low MDR-TB risk was defined as ≤four weeks previous TB treatment and high MDR-TB risk as >four weeks previous TB treatment, from congregate settings or with a known MDR-TB contact. Abbreviations: TB—tuberculosis, LPA—line probe assay, DST—drug susceptibility testing, HIV—human immunodeficiency virus, MTB—mycobacterium tuberculosis, PHC—primary health care.
Fig 2. A non-randomised stepped-wedge evaluation of…
Fig 2. A non-randomised stepped-wedge evaluation of TB yield in five PHC groups as they transitioned from the smear/culture to the Xpert® based algorithms in Cape Town.
This figure shows the TB diagnostic algorithm in place in 5 groups of PHC sites over the seven time-points (T1 to T7) used in the analysis. All sites initially had a smear/culture-based algorithm in place. The Xpert-based algorithm was introduced in August 2011 in Group A, in October 2011 in Group B, in February 2012 in Group C, in October 2012 in Group D and in February 2013 in Group E. With the exception of one PHC site, the groups represent all the sites within a sub-district. Abbreviations: TB—tuberculosis, PHC—primary health care.
Fig 3. TB yield in the smear/culture…
Fig 3. TB yield in the smear/culture and Xpert® based algorithms at PHC sites in Cape Town by time-point.
The graph shows the proportion of presumptive cases identified with TB (and 95% confidence intervals) in the smear/culture and Xpert-based algorithms as PHC sites changed from the former to the latter over seven time points (T1 to T7). Estimates derived from the binomial regression analysis were adjusted for clustering of cases at PHC sites. Time points were as follows: T1 = November 2010, T2 = May 2011. T3 = November 2011, T4 = May 2012, T5 = November 2012, T6 = May 2013, T7 = November 2013. Abbreviations: TB—tuberculosis, PHC—primary health care, CI—confidence interval.

References

    1. World Health Organisation. Global Tuberculosis Report 2013. 2013.
    1. World Health Organisation. Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB / RIF System. Policy Statement. 2011.
    1. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012;7(5):e36966 Available from: [cited 2013 Feb 28] 10.1371/journal.pone.0036966
    1. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M DN. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Collaboration. 2013;(1). Available from: [cited 2013 Aug 11]
    1. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007;11(5):485–95.
    1. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570–81.
    1. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369(9578):2042–9.
    1. Reid MJA, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9(3):173–84. 10.1016/S1473-3099(09)70043-X
    1. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis. 2007;196 Suppl S15–27.
    1. Dowdy DW, Brien MAO, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis. Int J Tuberc Lung Dis. 2008;12(9):1021–9.
    1. Shah M, Chihota V, Coetzee G, Churchyard G, Dorman SE. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis. 2013;13(1):352 Available from: [cited 2014 Jan 29]
    1. Statistics South Africa. Statistical release Mid-year population estimates. 2014.
    1. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–74.
    1. Van Den Handel T, Hampton KH, Sanne I, Stevens W, Crous R, Van Rie A. The impact of Xpert® MTB / RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015;19:392–8. 10.5588/ijtld.14.0653
    1. Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, et al. Impact of Xpert MTB / RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open forum infectious diseases. 2014; 1 (1): ofu038 (1–8). Available from [cited 2015 March 20] 10.1093/ofid/ofu038
    1. Lawn SD, Brooks S V, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011;8(7):e1001067 Available from: [cited 2014 Aug 13] 10.1371/journal.pmed.1001067
    1. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME. Which new diagnostics for tuberculosis, and when? J Infect Dis. 2012;205 Suppl S191–8.
    1. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495–505. 10.1016/S0140-6736(11)60438-8
    1. Sachdeva KS, Raizada N, Sreenivas A, Van’t Hoog AH, van den Hof S, Dewan PK, et al. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS One. 2015;10(5):e0126065 Available from: [cited 2015 May 28] 10.1371/journal.pone.0126065
    1. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLoS Med. 2014. December;11(12):e1001766 Available from: [cited 2014 Dec 10] 10.1371/journal.pmed.1001766
    1. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013;383(9915):424–35. 10.1016/S0140-6736(13)62073-5
    1. Middelkoop K, Bekker L-G, Myer L, Whitelaw A, Grant A, Kaplan G, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182(8):1080–5. 10.1164/rccm.201004-0598OC
    1. Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, et al. Articles Nationwide and regional incidence of microbiologically confi rmed pulmonary tuberculosis in South Africa, 2004–12 : a time series analysis. Lancet Infect Dis. 2015;3099(15):1–11.
    1. Langley I, Lin H-H, Egwaga S, Doulla B, Ku C-C, Murray M, et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Heal. 2014;2(10):e581–91. Available from: [cited 2015 Jun 5]
    1. Langley I, Doulla B, Lin H-H, Millington K, Squire B. Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions. Health Care Manag Sci. 2012;15(3):239–53. 10.1007/s10729-012-9201-3
    1. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006. 6:54 Available from: [cited 2014 Feb 19]
    1. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14(6):527–32. 10.1016/S1473-3099(13)70360-8
    1. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB / RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial. Plos Med. 2014;11(11):1–12. 10.1371/journal.pmed.1001760 [cited 2014 Nov 30]
    1. Naidoo P, du Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A, et al. A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. PLoS One. 2014;9(7):e103328 Available from: [cited 2014 Aug 1] 10.1371/journal.pone.0103328
    1. Cox HS, Daniels JF, Muller O, Nicol MP, Cox V, Van Cutsem G, et al. Impact of Decentralized Care and the Xpert MTB / RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa. Open Forum Infectious Diseases. 2015;2(1):ofv014). Available from: [cited 2015 Jun 9] 10.1093/ofid/ofv014
    1. Toit E, Squire SB, Dunbar R, Machekano R, Madan J, Beyers N, et al. Comparing multidrug-resistant tuberculosis patient costs under molecular diagnostic algorithms in South Africa. Int J Tuberc Lung Dis.2015;19(8):960–968. 10.5588/ijtld.14.0703
    1. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011. November;8(11):e1001120 Available from: [cited 2014 Jan 29] 10.1371/journal.pmed.1001120
    1. Churchyard G, McCarthy K, Fielding KL, Stevens W, Chihota V, Nicol M, et al. Effect of Xpert MTB / RIF On Early Mortality in Adults With Suspected TB: A Pragmatic Randomized Trial. CROI. 2014; Abstract.

Source: PubMed

3
Tilaa